PALO
Palo Protocol — Nasal
KPV 10 mg Nasal — Palo Protocol — coming soon

Palo Protocol: Nasal

KPV 10 mg Nasal

Immune

10 mg in 10 ml · 15 ml bottle

The route makes mechanistic sense for a mucosal anti-inflammatory. Mechanistic sense is not the same as evidence, and not the same as a lawful pathway.

Not available for purchase

What we know

Mechanism
The C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory activity at mucosal surfaces — the rationale for the intranasal route.
Evidence state
Preclinical, with mechanistic interest in mucosal inflammation.
Regulatory note
Not approved and not a lawful dietary ingredient. Supplier marks the nasal range 'For Research Use Only'.

Disclaimer

This product is not available for purchase. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure or prevent any disease. Nothing on this page is medical advice. Palo lists this compound for transparency about our supply partnerships; any future availability would run through a licensed prescriber and a compounding pharmacy, not through this website.